An open-label randomized phase II study that evaluated osimertinib combined with carboplatin-pemetrexed in comparison with osimertinib monotherapy in patients with EGFRm NSCLC who experienced disease progression associated with the emergence of EGFR T790M resistance mutation during first-line EGFR-TKI therapy failed to demonstrate prolongation of progression-free survival (20). This evidence concerns the gene EGFR and non-small cell lung carcinoma.